The DOI matches its Crossref record, with a small difference in title or year.
Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance
Abstract
Mode of action of 5-fluorocytosine (5-FC) and mechanisms of resistance to the drug are discussed on the basis of experiments performed with Candida albicans ATCC 26790 and with 50 selected clinical isolates of C. albicans belonging to serological type A or B and representing various degrees and models of 5-FC resistance (sensitivity). Incorporation of 5-fluorouridylic acid into RNA appeared as a prerequisite to antifungal activity, although at a given incorporation rate, growth inhibition varied considerably from one strain to the other. The amino acid pool was unbalanced, and there was evidence for disturbance of protein synthesis. These dysfunctions of RNA probably account for growth inhibition and cell death, whereas up to the present, there was no proof of formation of 5-fluorodeoxyuridylic acid nor of subsequent inhibition of thymidylate synthetase. Incorporation of fluorinated pyrimidine into RNA was lower in normally sensitive type B strains than in normally sensitive ones of type A, whereas the frequency of 5-FC-resistant mutants was the same. The two serological types did not differ in the activity of cytosine permease nor in that of cytosine deaminase. Among 29 clinical isolates with 5-FC resistance (or impaired sensitivity) no instance of cytosine permease deficiency was found. Two isolates (belonging to the serological type A) were deficient in cytosine deaminase, whereas the majority was probably deficient in uridine monophosphate pyrophosphorylase or had a surplus of de novo synthesis of pyrimidines. Relative 5-FC resistance was more common than complete resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cited by
Sorted by citations
Items 201–250 of 250
Modern fungicidal substances (a review)
Rudzit, É. A. (1978) · Pharmaceutical Chemistry Journal · doi:10.1007/bf00777626 · Cited by 2
Devarasetty, K., Tharikoppula, G., Sridhar, T., Eppakayala, L., Kyasani, M., Arumugam, P., & Pusuluri, S. (2015) · Synthetic Communications · doi:10.1080/00397911.2015.1135349 · Cited by 2
Mukherjee, P. K., & Wang, M. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-5 · Cited by 2
Bennett, J. E. (1985) · Médecine et Maladies Infectieuses · doi:10.1016/s0399-077x(85)80006-8 · Cited by 2
Problems in antimycotics from the viewpoint of their mechanisms of action.
Uno, J. (1985) · Japanese Journal of Medical Mycology · doi:10.3314/jjmm1960.26.133 · Cited by 2
Anti-Candida activity of killer toxins from the yeast Williopsis mrakii
Hodgson, V. J. (1993) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 2
Сулейман, М. М. (2010) · UpSpace Institutional Repository (University of Pretoria) · Cited by 2
Edwards, D. (1980) · doi:10.1007/978-1-349-16360-1_11 · Cited by 2
Invasive Candidiasis in the Intensive Care Unit
Krishnan, S., & Ostrosky-Zeichner, L. L. (2010) · Hospital Practice · doi:10.3810/hp.2010.04.298 · Cited by 1
STRUCTURAL AND BIOCHEMICAL STUDIES OF RIBONUCLEOTIDE REDUCTASE INHIBITION BY dATP AND Sml1
Wijerathna, S. R. (2012) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Németh, T., Gácser, A., & Nosanchuk, J. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20709-7 · Cited by 2
Interventions for the management of esophageal candidiasis in immunocompromised patients
Ōnishi, A., Iwasaku, M., Sato, A., & Furukawa, T. A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011938 · Cited by 1
Design, Synthesis, and Antimicrobial Activity of Novel 6-Oxopyrimidin-1(6H)-yl Benzamide Derivatives
Devarasetty, K., Vantikommu, J., Anireddy, J. S., & Srinivas, P. (2019) · Russian Journal of General Chemistry · doi:10.1134/s1070363219040236 · Cited by 1
MacCallum, D. M. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755388.003.0046 · Cited by 1
Studies on the mechanism of resistance to 5-fluorocytosine, an antifungal agent, in fungi.
Miyamoto, C., Fujiwara, A., & Fujiwara, M. (1977) · Japanese Journal of Medical Mycology · doi:10.3314/jjmm1960.18.92 · Cited by 1
Susceptibility testing and antifungal agents
Merz, W. G. (1980) · Clinical Microbiology Newsletter · doi:10.1016/s0196-4399(80)80199-1 · Cited by 1
Pediatric Antifungal Chemotherapy
Koldin, M. H., & Medoff, G. (1984) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30997-5 · Cited by 1
Chapter 11: Antifungal Agents.
Cartwright, R. Y. (1976) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61394-9
Reverté, F. M. (2002) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Flucytosine for treatment of Candida albicans in H1N1-positive patient
Samra, T., Yadav, A., Banerjee, N., Pawar, M., & Deepak, D. (2010) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.70398
da Rosa, J. L. (2012) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/w35r-7869
“As a nucleotide analogue, it impedes DNA synthesis (Polak and Scholer, 1975), 39 suggesting that mutants defective for replication fork stability may be more sensitive to this compound.”
Flucytosine, Amphotericin Bによる肺真菌症と脳真菌症の化学療法の解析
松本, 慶., 政利, 井., 良夫, 宇., 行雄, 野., 今岡, 誠., & 貴和雄, 渡. (1980) · Chemotherapy · doi:10.11250/chemotherapy1953.28.382
Mechanism of Action of Antifungal Chemotherapeutics
Yamaguchi, H. (1977) · Japanese Journal of Medical Mycology · doi:10.3314/jjmm1960.18.342
Yamaguchi, H., Hiratani, T., & Iwata, K. (1976) · Japanese Journal of Medical Mycology · doi:10.3314/jjmm1960.17.212
Studies on Antifungal Mechanism of 5-Fluocytosine
Yamaguchi, H., & Iwata, K. (1976) · Japanese Journal of Medical Mycology · doi:10.3314/jjmm1960.17.201
Molecular Targets for Anticandidal Chemotherapy
Milewski, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_21
Németh, T., Gácser, A., & Nosanchuk, J. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-819990-9.20709-9
Drew, R. H. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-12
Warnock, D. W. (2011) · Wiley eBooks · doi:10.1128/9781555816728.ch126
Mouton, J. W., & Verweij, P. E. (2009) · Springer eBooks · doi:10.1007/978-90-481-2408-4_18
RONG, Z., 宾文, 刁有江, 杨剑, Liu, T., 彭俊平, & 金奇 (2009) · Science in China Series C-Life Sciences (in Chinese) · doi:10.1360/zc2009-39-7-699
Thompson, G. R., & Patterson, T. F. (2014) · Springer eBooks · doi:10.1007/978-3-662-44000-1_15
Evaluation of antibacterial and antifungal activities of N-benzylthienopyrimidinone derivatives
Diédhiou, A., BALDE, M., Ndoye, I., THIAM, M., TIRÉRA, H., Abdoulaye, D. I. O. P., Gueye, R., Tine, Y., Dieng, A., Ndoye, S. F., et al. (2022) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v12i3.5449
(2022) · International Journal of Biology Pharmacy and Allied Sciences · doi:10.31032/ijbpas/2022/11.12.6682
Supplementary material A: Commentaries
Ainsworth, S. B. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198840787.005.0001
Synthesis and Biological Significance of Pyrimidine Derivatives as New Anti-bacterial Agents
Pathak, A., & Kumar, M. (2022) · THE SCIENTIFIC TEMPER · doi:10.58414/scientifictemper.2022.13.2.32
Intestinal Microbiome and Its Impact on Metabolism and Safety of Drugs
Chu, X. Y., & Ho, P. C. (2023) · Wiley eBooks · doi:10.1002/9781119660699.ch25
MDR in Candida: The Real Storm
Srivastava, P., Tiwari, S., Kumar, M., Murhekar, M. V., & Dwivedi, G. R. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_4
Hussein, R. N. (2025) · Journal of Molecular and Engineering Materials · doi:10.1142/s2251237325500042
Effects of novel organoantimony compounds on the fungal pathogen Cryptococcus neoformans
Cotton, K., Lieberman, J. A., Gerasimchuk, N., & Wozniak, K. L. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002058 · Cited by 1
“The pyrimidines (5-flucytosine) inhibit DNA replication or protein synthesis by becoming incorporated in DNA or RNA, respectively [17, 18].”
Bubna, A. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-3791-4_19
典巳, 山., 直志, 西., 富由, 伊., 谷村, 英., & 大山, 昭. (1982) · Chemotherapy · doi:10.11250/chemotherapy1953.30.1305
El‐Sayed, A. S. A., Rady, A. M., Mohamed, H. T., Zein, N., Yassin, M. A., Mohamed, N. Z., Hassan, A. E., Amer, M. M., El-Sharakawy, R., El-Sharkawy, A. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26560430
Spt7 Deletion Reveals Vulnerabilities in Cryptococcus neoformans Stress Adaptation and Virulence
Yu, C. K., Stephenson, C. J., Schulz, B. L., & Fraser, J. A. (2026) · Microorganisms · doi:10.3390/microorganisms14010095
“In contrast to the pronounced responses observed under other conditions, these findings suggest that Spt7 is not broadly required for ER stress tolerance, ROS defence, or chitin remodelling [53–57].”
La D-cateslytine : un nouvel agent antifongique pour le traitement de la candidose buccale
Dartevelle, P. (2019) · theses.fr (ABES) · doi:10.70675/2fcc1c48z0776z40d4z8d81z66bc68fa13a9
Emerging Antifungal Resistance in Ocular Infections
de Oliveira, H. C., Tabuse, A. M., Höfling-Lima, A. L., & Rodrigues, A. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-19923-2_3
Taş, E., Çetin, B., Yılmazer, A. N., & Işık, T. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12737-3
“Flucytosine is a fluorinated pyrimidine analogue that enters fungal cells via cytosine permease and is subsequently converted into active fluorinated metabolites that inhibit both DNA and RNA synthesis [9].”
Mokoka, T. (2007) · UpSpace Institutional Repository (University of Pretoria)
Metadata
- Authors
- Polak, A., & Scholer, H. J.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- ORCID
- Polak, Annemarie
- Venue
- Chemotherapy
- Publisher
- S. Karger AG
- Published
- 2009-05-25
- Volume
- 21
- Issue
- 3-4
- Pages
- 113-130
- ISSN
- 0009-3157 (ISSN-L)
- 1421-9794
- OpenAlex
- W2072785474
- Cited by
- 250
- References
- 0
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 10 · 2023: 12 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 7 · 2018: 7 · 2017: 4 · 2016: 5 · 2015: 2 · 2014: 8 · 2013: 4 · 2012: 6
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- 5-fluorocytosine, Candida albicans, antifungal resistance, mechanism of action, cytosine deaminase, protein synthesis inhibition, clinical isolates
- MeSH terms
- Candida albicans, Cell Division, Cytidine Deaminase, Cytosine, Drug Resistance, Microbial, Flucytosine, RNA, Serotyping, Uracil Nucleotides, Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
